New therapies continue to raise efficacy bar in hidradenitis suppurativa

Durability data from AAD show Bimzelx could soon become the new standard of care for moderate to severe hidradenitis suppurativa, and data at the conference from Acelyrin and Lilly highlighted the potential for other programs to raise the bar for efficacy in HS.

At the 2023 American Academy of Dermatology (AAD) annual meeting in New Orleans, UCB S.A. (Euronext:UCB) presented detailed data from the Phase III BE HEARD I and BE HEARD II trials of IL-17A and IL-17F inhibitor Bimzelx bimekizumab dosed once every two weeks that showed a 19-20% placebo-adjusted improvement in HiSCR50 response rate at week 16, the primary endpoint for both studies (p=0.006 and p=0.003)...